John M. Rothman
Corporate Officer/Principal bei TYME TECHNOLOGIES, INC.
Aktive Positionen von John M. Rothman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TYME TECHNOLOGIES, INC. | Corporate Officer/Principal | 19.08.2020 | - |
Karriereverlauf von John M. Rothman
Ehemalige bekannte Positionen von John M. Rothman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
RACE ONCOLOGY LIMITED | Chief Tech/Sci/R&D Officer | - | 01.10.2019 |
AYALA PHARMACEUTICALS, INC. | Chief Operating Officer | 06.11.2009 | 09.12.2011 |
Chief Tech/Sci/R&D Officer | 01.03.2005 | 01.03.2013 | |
Corporate Officer/Principal | 09.12.2011 | 13.08.2012 |
Ausbildung von John M. Rothman
Tulane University School of Medicine | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Australien | 2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
RACE ONCOLOGY LIMITED | Health Technology |
Private Unternehmen | 2 |
---|---|
Tyme Technologies, Inc.
Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
Advaxis, Inc.
Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
- Börse
- Insiders
- John M. Rothman
- Erfahrung